# Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.

> **NCT06047535** · PHASE4 · NOT_YET_RECRUITING · sponsor: **SciClone Pharmaceuticals** · enrollment: 62 (estimated)

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** Naxitamab

## Key facts

- **NCT ID:** NCT06047535
- **Lead sponsor:** SciClone Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-10-31
- **Primary completion:** 2027-06-15
- **Final completion:** 2027-08-15
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06047535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06047535, "Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06047535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*